Contact Us
Drug Search Results
More Filters [+]

Namilumab

Alternative Names: namilumab
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Mechanisms of Action: GM-CSF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Namilumab

Countries in Clinic: Belgium, France, Germany, Netherlands, Turkey, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Sarcoidosis, Pulmonary

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
KIN-1902-2001

P2

Unknown Status

Sarcoidosis, Pulmonary

2025-07-20

Resolve-Lung

P2

Active, not recruiting

Sarcoidosis, Pulmonary

2024-11-15

RESOLVE-Lung

P2

Active, not recruiting

Sarcoidosis, Pulmonary

2024-10-16

Recent News Events

Date

Type

Title

12/03/2024

News Article

 Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

12/03/2024

News Article

 Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

04/25/2024

News Article

 Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

11/13/2023

PubMed

 Compartment-specific protein interactions in beryllium lung disease.

11/17/2022

News Article

 Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)

03/01/2022

PubMed

 Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.

09/01/2020

PubMed

 Pharmaco-Immunomodulatory Therapy in COVID-19.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions